KR101558184B1 - Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium - Google Patents
Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium Download PDFInfo
- Publication number
- KR101558184B1 KR101558184B1 KR1020090032841A KR20090032841A KR101558184B1 KR 101558184 B1 KR101558184 B1 KR 101558184B1 KR 1020090032841 A KR1020090032841 A KR 1020090032841A KR 20090032841 A KR20090032841 A KR 20090032841A KR 101558184 B1 KR101558184 B1 KR 101558184B1
- Authority
- KR
- South Korea
- Prior art keywords
- leaf extract
- selenium
- antioxidant
- composition
- grape leaf
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 22
- 239000011669 selenium Substances 0.000 title claims abstract description 22
- 230000003712 anti-aging effect Effects 0.000 title description 6
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 44
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 39
- 235000021028 berry Nutrition 0.000 claims abstract description 21
- 241001593968 Vitis palmata Species 0.000 claims abstract description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 14
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 12
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 7
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 244000207620 Euterpe oleracea Species 0.000 claims description 3
- 235000012601 Euterpe oleracea Nutrition 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 3
- 240000007651 Rubus glaucus Species 0.000 claims description 3
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 3
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 3
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 3
- 235000003650 acai Nutrition 0.000 claims description 3
- 235000021029 blackberry Nutrition 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 235000004634 cranberry Nutrition 0.000 claims description 3
- 241000219095 Vitis Species 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims 4
- 206010051246 Photodermatosis Diseases 0.000 abstract description 8
- 230000008845 photoaging Effects 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 235000006708 antioxidants Nutrition 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000007760 free radical scavenging Effects 0.000 description 14
- 240000006365 Vitis vinifera Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- -1 intracellular uptake Chemical compound 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000243535 Lecythis zabucajo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000012026 paradise nut Nutrition 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000000275 Persicaria hydropiper Species 0.000 description 1
- 235000017337 Persicaria hydropiper Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 피부 개선을 위한 항산화용 조성물에 관한 것으로서, 보다 상세하게는 적포도잎 추출물, 베리 혼합물 및 셀레늄을 함유함으로써 이들을 개별적으로 사용했을 때 보다 항산화제로서 상승 작용이 있으며, 혈중 항산화력을 증가시키고 UV에 의한 광노화를 개선시킬 수 있는 항산화용 조성물에 관한 것이다.The present invention relates to a composition for antioxidation for improving skin, and more particularly, it relates to a composition for preventing and treating skin, and more particularly, to a composition containing red grape leaf extract, berry mixture and selenium, And is capable of improving photo-aging caused by UV.
적포도잎 추출물, 베리 혼합물, 셀레늄, 광노화, 항산화 Red grape leaf extract, berry mixture, selenium, photo-aging, antioxidant
Description
본 발명은 피부 개선을 위한 항산화용 조성물에 관한 것으로서, 보다 상세하게는 적포도잎 추출물, 베리 혼합물 및 셀레늄을 함유함으로써 이들을 개별적으로 사용했을 때 보다 항산화제로서 상승 작용이 있으며, 혈중 항산화력을 증가시키고 UV에 의한 광노화를 개선시킬 수 있는 항산화용 조성물에 관한 것이다.The present invention relates to a composition for antioxidation for improving skin, and more particularly, it relates to a composition for preventing and treating skin, and more particularly, to a composition containing red grape leaf extract, berry mixture and selenium, And is capable of improving photo-aging caused by UV.
노화를 촉진하는 원인들은 여러 가지가 있으나 그 중에서도 활성 산소계(ROS: Reactive Oxygen species)가 상당히 주요한 원인 중 하나인 것으로 받아들여지고 있다. 이러한 활성 산소는 에너지 대사과정, 면역 반응 등에서 필수 불가결하게 생성되며, 외부의 유해 환경에 의해서도 유발되는 피할 수 없는 자극이다. 활성 산소는 반응성이 매우 커서 체내에서 DNA 변성, 과도한 신호전달 유발 및 단백질 변성 등을 초래하여 건강에 해로운 영향을 누적하는 일련의 반응을 일으키게 된 다. 이러한 유해한 반응들은 생체 내에 존재하는 항산화 물질(uric acid, vit.C, vit.E 등) 또는 항산화 효소(Glutathione peroxidase, superoxide dismutase, catalse 등)에 의해 정교하게 그 항상성을 유지하도록 되어 있다. 그러나, 내인성 노화에 따른 항산화 시스템의 노쇠와 지속적인 유해 자극에 의한 활성 산소의 집적은 이러한 균형을 깨뜨려 건강을 해치게 되며 노화를 촉진시키고, 피부 질환, 피부암, 동맥경화 및 혈전과 같은 각종 질병을 유발하기도 한다(Laure Rittie et al., Ageing Research Reviews, 1, 705-720, 2002; Cutler RG, Annals of the New York Academy of Sciences, 1055, 93-135, 2005). There are many reasons for promoting aging, but Reactive Oxygen species (ROS) is considered to be one of the major causes. This active oxygen is indispensable in energy metabolism, immune response, etc., and it is inevitable irritation caused by external harmful environment. Active oxygen is highly reactive and causes DNA degeneration, excessive signal transduction and protein denaturation in the body, resulting in a series of reactions accumulating adverse health effects. These harmful reactions are supposed to preserve their homeostasis by antioxidants (uric acid, vit.C, vit.E etc.) or antioxidant enzymes (Glutathione peroxidase, superoxide dismutase, catalase, etc.) in vivo. However, the aging of the antioxidant system due to the endogenous aging and the accumulation of active oxygen by the continuous harmful stimuli breaks this balance, harming health, promoting aging, causing various diseases such as skin diseases, skin cancer, arteriosclerosis and thrombosis ( Laure Rittie et al., Aging Research Reviews, 1, 705-720, 2002; Cutler RG, Annals of the New York Academy of Sciences, 1055, 93-135, 2005).
따라서, 활성 산소계의 형성을 억제하거나, 형성된 활성 산소계를 제거하는 항산화 물질에 대한 관심이 날로 증가하고 있다. 항산화 물질은 인체 내에 자연적으로 존재하는 것과 외부에서 투여해 주는 것으로 나눌 수 있는데 인체 내에 자연적으로 존재하는 항산화 물질로는 과산화 억제효소(SOD: superoxide dismutase), 글루타치온(glutathione), 퍼옥시다아제(peroxidase) 및 카탈라아제(catalase) 등의 효소가 있으며, 외부에서 투여해 주는 것으로는 캠프페롤(kaempferol), 카테킨(catechin) 및 제니스테인(genistein) 등의 피토케미컬(phytochemical); 비타민 E, 비타민 C 및 베타카로틴; 및 셀레늄 등의 미네랄이 있다. Accordingly, there is an increasing interest in antioxidants that inhibit the formation of active oxygen systems or remove the formed active oxygen system. Antioxidant substances can be divided into two groups: naturally occurring in the body and externally administered. Antioxidants naturally present in the body include superoxide dismutase (SOD), glutathione, peroxidase and Catalase and the like, and phytochemicals such as kaempferol, catechin and genistein are externally administered. Vitamin E, vitamin C and beta carotene; And minerals such as selenium.
그러나, 이러한 항산화 물질의 사용량이 너무 적으면 충분한 항산화 효과를 기대할 수 없으며, 지나치게 증가할 경우에는 오히려 일부 효소의 활성을 억제시키는 등의 부작용에 의해 체내에서 생성된 활성 산소를 적절하게 제거시키지 못하여 이들에 의한 조직의 손상을 유발할 수도 있어서 바람직하지 않다. 따라서, 항산화 물질을 함께 사용함으로써 상승 작용을 나타내는 조성물에 대한 관심이 날로 증가하고 있다. However, if the amount of the antioxidant used is too small, a sufficient antioxidative effect can not be expected. If the amount of the antioxidant is excessively increased, the active oxygen produced in the body can not be properly removed due to side effects such as inhibition of activity of some enzymes. Which may cause damage to the tissue. Therefore, there is a growing interest in compositions that exhibit synergy by using antioxidants in combination.
한국등록특허 제0835866호 "항산화 물질의 산화 촉진제로서의 부작용을 방지한 항산화 조성물"에서 항산화 물질의 체내에서의 시간에 따른 반응성을 평가하고 그 효능의 지속시간을 증가시킬 수 있는 항산화 조성물에 대하여 개진하였다. 적포도잎 추출물에 대해서는 미국공개특허공보 제2005/048008호에는 항염증 조성물로써 적포도잎(Vitis Vinifera)의 추출물을 항염증 조성물로 포함하는 항노화 화장 조성물에 대한 내용이 개시되어 있으며, 일본공개특허공보 제2001-081008호에는 포도잎 추출물 등과 탄소 원자수 4∼6의 당알코올을 배합한 노화 방지 효능이 있는 거친 피부 방지, 피부 개선용 조성물 또는 노화방지용 조성물이 개시되어 있으나 적포도잎 추출물과 다른 항산화 원료가 갖는 시너지 효능에 대해서는 활용이 부족한 실정이다. Korean Patent No. 0835866 discloses an antioxidant composition capable of evaluating the reactivity of an antioxidant in the body over time and increasing the duration of its efficacy in the "antioxidative composition preventing side effects as an oxidation promoter of antioxidants" . As for the red grape leaf extract, US Patent Application Publication No. 2005/048008 discloses an anti-aging cosmetic composition containing an extract of Vitis Vinifera as an anti-inflammatory composition as an anti-inflammatory composition, Patent Publication No. 2001-081008 discloses a composition for preventing rough skin, a composition for improving skin or an anti-aging composition having an anti-aging effect, which comprises grape leaf extract and the like and sugar alcohol having 4 to 6 carbon atoms, The synergistic effects of other antioxidant ingredients are in short use.
이에, 본 발명자들은 적포도잎 추출물에 여러 항산화 물질을 추가하여 체내 반응성과 항산화 효능에 대한 시너지 효과를 평가하였으며, 그 결과를 통해 궁극적으로 광노화 개선에 탁월한 효능이 있는 항산화용 조성물을 개발함으로써 본 발명을 완성하였다. Accordingly, the inventors of the present invention evaluated various synergistic effects on body reactivity and antioxidant efficacy by adding various antioxidants to the grape leaf extract, and as a result, they have developed a composition for antioxidation which is ultimately effective for improving photoaging, .
따라서, 본 발명의 목적은 광노화 개선에 탁월한 효능이 있는 항산화용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for antioxidation having an excellent effect for improving photoaging.
상기한 목적을 달성하기 위하여, 본 발명에서는 적포도잎 추출물, 베리 혼합물 및 셀레늄을 유효성분으로 함유하는 항산화용 조성물을 제공한다.In order to achieve the above object, the present invention provides an antioxidative composition comprising a red grape leaf extract, a berry mixture, and selenium as an active ingredient.
본 발명에 따른 항산화용 조성물은 유효성분으로서 적포도잎 추출물, 베리 혼합물 및 셀레늄을 모두 혼합하여 사용함으로써 각 성분을 개별적으로 사용했을 때 보다 항산화제로서 상승 작용이 있었으며, 항산화 물질의 복용 시에 발생할 수 있는 부작용을 경감시키고 체내 항산화 이용률을 증가시키는 효과를 얻을 수 있었다. 또한, 최적 조합비의 조성물을 장기 복용한 경우에도 동량으로 단독 복용한 경우보다 여러 가지 항산화 지표에서 더욱 우수한 항산화 효능을 얻을 수 있었다. 따 라서, 본 발명에 따른 항산화 조성물은 통상의 음료, 건강 보조 식품 또는 피부 미용제 등에 적용할 경우 자유기의 소거제(항산화제)로서 건강 증진 및 노화 방지에 커다란 효과를 나타낼 수 있을 것으로 기대된다. The composition for antioxidation according to the present invention has a synergistic effect as an antioxidant agent when each component is used in combination with a combination of red grape leaf extract, berry mixture and selenium as an effective ingredient. And the antioxidant activity in the body was increased. In addition, even when the composition of the optimal combination ratio was administered for a long period of time, antioxidant efficacy was further improved in various antioxidant indexes compared to the case of using the same amount alone. Accordingly, the antioxidant composition according to the present invention is expected to have a great effect on health promotion and anti-aging as a free radical scavenger (antioxidant) when applied to ordinary beverages, health supplements or skin aesthetic agents .
본 발명에서 사용하는 적포도잎 추출물은 포도(Vitis vinifera L.) 나무 중에서 특히, 잎이 붉은 색을 띠는 유럽산 포도의 붉은 잎(Folia vitis viniferae )에서 수용성 성분을 추출하여 분말화한 소재이며, 전체 분말에 대하여 총폴리페놀을 10% 이상 함유하고 있어 기능성 소재로서 주목받고 있다. 본 발명에서 사용하는 적포도잎 추출물은 당업계에 잘 알려진 방법을 통해 물 또는 유기용매로 추출할 수 있다. 본 발명에 사용하는 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트, 클로로포름 및 이들 유기용매와 물의 혼합용매로 이루어진 군에서 선택될 수 있으며, 바람직하게는 80% 에탄올을 사용한다. 이때, 추출온도는 10∼80℃가 바람직하며, 6∼24시간 동안 추출할 수 있다. 상기 추출온도 및 추출시간을 벗어나면 추출 효율이 떨어지거나 성분의 변화가 생길 수 있다.The red grape leaf extract used in the present invention is a material obtained by extracting a water-soluble component from a red leaf ( Folia vitis viniferae ) of a grape (Vitis vinifera L.) It contains not less than 10% of total polyphenol as a whole powder and is attracting attention as a functional material. The grape leaf extract used in the present invention can be extracted with water or an organic solvent through a method well known in the art. The organic solvent used in the present invention may be selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate, chloroform and a mixed solvent of these organic solvents and water, preferably 80% ethanol. At this time, the extraction temperature is preferably 10 to 80 캜, and it can be extracted for 6 to 24 hours. If the extraction temperature and the extraction time are exceeded, the extraction efficiency may be deteriorated or the component may be changed.
본 발명에서 사용하는 베리 혼합물은 석류(Pomegranate), 라즈베리(Raspberry), 블랙베리(Blackberry), 아카이(Acai), 크랜베리(Cranberry) 및 블루베리(Blueberry)로 이루어진 군에서 선택된 과실을 2종 이상 혼합하여 제조한 것으로서, 상기 과실들을 건조하여 분말로 만든 후 혼합하거나 또는 각 과실의 추출물을 동결건조한 분말을 혼합하여 제조할 수 있으나, 이에만 한정되는 것은 아니 다.The berry mixture used in the present invention may be a mixture of two or more kinds of fruits selected from the group consisting of pomegranate, raspberry, blackberry, acai, cranberry and blueberry. The powder may be prepared by drying the powdered fruits and then mixing the powders, or by mixing the powdered fruits of each fruit with freeze-dried powder. However, the present invention is not limited thereto.
본 발명에서 사용하는 셀레늄은 파라다이스넛으로부터 추출한 셀레늄 급원 원료를 사용하였고, 파라다이스넛추출 분말 중량당 0.1%의 셀레늄이 함유되어 있다. The selenium used in the present invention is selenium source material extracted from paradise nut, and 0.1% selenium is contained per weight of paradise nut extract powder.
적포도잎 추출물에 들어 있는 대표적인 폴리페놀인 케르세틴류(Quercetin) 또는 플라본류(Flavone) 등과 같은 성분들 자체도 항산화 활성이 우수한 편이지만, 항산화 성분들은 단독 사용 시보다 혼합 사용 시에 지속적이고 월등한 효과를 나타내는 경우가 많다. 그러므로 이들과 함께 다른 항산화 성분들을 최적 배합하여 항산화 효능이 더욱 뛰어난 조성물을 개발하고자 하였고, 본 발명에서 적포도잎 추출물에 항산화 미네랄인 셀레늄과 안토시아닌이 풍부하게 들어있는 베리 혼합물을 포함하는 항산화 조성물을 제공하게 되었다.Components such as Quercetin or Flavone, which are representative polyphenols contained in red grape leaf extract, are excellent antioxidant activity. However, antioxidant components are superior to each other in continuous use and superior Effects often occur. Therefore, in order to develop a composition having an antioxidative effect that is more optimal than other antioxidant components, the present invention provides an antioxidant composition comprising an antioxidant mineral, selenium and an anthocyanin-rich berry mixture, .
본 발명에서는 적포도잎 추출물, 베리 혼합물 및 셀레늄을 동시에 함유하는 항산화 조성물을 제공한다.The present invention provides an antioxidative composition containing red grape leaf extract, berry mixture and selenium simultaneously.
본 발명의 항산화 조성물에서 적포도잎 추출물, 베리 혼합물 및 셀레늄은 1:1:1 내지 10:1:1의 중량비로 혼합되는 것이 바람직하다. 이때 상기 유효성분들을 혼합한 혼합물의 함량은 전체 조성물 총 중량에 대하여 0.1∼80 중량%가 바람직하다. 상기 혼합물의 함량이 0.1 중량% 미만인 경우에는 유효한 효능을 기대하기 어렵고, 80 중량%를 초과하는 경우에는 제형화가 어려운 단점이 있다. In the antioxidant composition of the present invention, the grape leaf extract, the berry mixture and the selenium are preferably mixed in a weight ratio of 1: 1: 1 to 10: 1: 1. At this time, the content of the mixture of the active ingredients is preferably 0.1 to 80% by weight based on the total weight of the composition. When the content of the mixture is less than 0.1% by weight, it is difficult to expect effective efficacy. When the content is more than 80% by weight, formulation is difficult.
본 발명에 의한 항산화 조성물은 체내 활성 산소계를 제거하고 항산화 효소의 활성 저하를 방지함으로써 노화를 방지할 수 있다.The antioxidant composition according to the present invention can prevent aging by eliminating the active oxygen system in the body and preventing the activity of the antioxidant enzyme from being lowered.
본 발명에 의한 항산화 물질은 각 물질간의 비율과 성상에 따라 당업계에 잘 알려진 기술에 의하여 정제 및 캡슐 형태로 안정하게 한 조성물 내에 함유될 수 있으며, 항산화제 복합의 광노화 개선 및 노화 방지제 조성물로 제형화될 수 있으나, 이에만 한정되는 것은 아니다. The antioxidant according to the present invention may be contained in a composition stabilized in tablets and capsules by a technique well known in the art depending on the ratio and properties of each substance, But is not limited thereto.
또한 본 발명에 의한 항산화 조성물은 통상의 음료, 건강 보조 식품 및 피부 미용제 등에 적용할 경우 자유라디칼의 소거제(항산화제)로서 건강 증진 및 노화 방지에 커다란 효과가 있다. Further, the antioxidant composition according to the present invention has a great effect on health promotion and anti-aging as a free radical scavenging agent (antioxidant) when it is applied to ordinary beverages, health supplements and skin aesthetic agents.
이하, 본 발명의 내용을 실시예 및 시험예를 통하여 보다 구체적으로 설명한다. 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니고, 당업계에서 통상적으로 주지된 변형, 치환 및 삽입 등을 수행할 수 있으며, 이에 대한 것도 본 발명의 범위에 포함된다.Hereinafter, the present invention will be described more specifically with reference to examples and test examples. It is to be understood that the scope of the present invention is not limited to these embodiments and that variations, substitutions, and insertions conventionally known in the art can be carried out, And this is included in the scope of the present invention.
[참조예 1] 적포도잎 추출물 제조[Reference Example 1] Preparation of red grape leaf extract
적포도잎 1 kg을 수거하여 80% 에탄올 수용액 5 ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 적포도잎 추출물 155 g을 얻었다. 1 kg of red grape leaves were collected and 5 L of 80% ethanol aqueous solution was added, and the mixture was refluxed three times and immersed at 15 ° C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain 155 g of a grape leaf extract.
[참조예 2] 베리 혼합물 제조[Reference Example 2] Preparation of berry mixture
동일한 분량의 석류, 라즈베리, 블랙베리, 아카이, 크랜베리 및 블루베리 과실을 건조하고 분말화한 후 혼합하여 베리 혼합물을 제조하였다.The same amount of pomegranate, raspberry, blackberry, acai, cranberry and blueberry fruit were dried and powdered and mixed to prepare a berry mixture.
[시험예 1] 시험관 내에서(in vitro) 자유라디칼 소거 활성[Test Example 1] In vitro free radical scavenging activity
하기 표 1에 기재된 대조군, 비교예 1∼3 및 실시예 1의 단일 물질 혹은 복합물질의 자유기 소거능의 변화를 평가하는 실험을 수행하였다. Experiments were conducted to evaluate changes in free radical scavenging ability of the single substance or complex substance of the control group, Comparative Examples 1 to 3 and Example 1 shown in the following Table 1.
측정 방법은 1,1-디페닐-2-피크릴-히드라질(DPPH: 1,1-diphenyl-2-picryl-hydrazyl) 방법으로, 이때 시약은 미국 시그마사로부터 구입하여 사용하였다. 이 시약은 비교적 안정한 자유라디칼로 존재하기 때문에, 자유라디칼 소거작용을 확인하는 과정에서 일차적으로 시험관적인 방법으로 사용되고 있다. The measurement method was 1,1-diphenyl-2-picryl-hydrazyl (DPPH) method. The reagent was purchased from Sigma, USA. Since this reagent exists as a relatively stable free radical, it is used primarily as an in vitro method in confirming the free radical scavenging action.
DPPH 자유라디칼 소거활성의 측정에 사용하는 성분들의 농도는 각각 4 ppm, 20 ppm 및 100 ppm으로 하였다. 상기 농도의 성분을 96웰 플레이트에 각각 넣고 여기에 100 μM의 에탄올 용액으로 제조된 DPPH를 첨가하여 용액의 총부피가 200 ml가 되도록 하였다. 이것을 37℃에서 30분간 방치한 후 520 nm ELISA 리더기로 흡광도를 측정하였다. 자유라디컬 소거활성은 다음의 수학식 1로 산출하였다. The concentration of the components used for measuring DPPH free radical scavenging activity was 4 ppm, 20 ppm and 100 ppm, respectively. The components of the above concentrations were placed in a 96-well plate, and DPPH prepared from 100 μM ethanol solution was added thereto to make the total volume of the
(단, A는 성분을 처리하지 않은 대조군 웰의 흡광도이며, B는 각각의 성분을 처리한 비교예 1∼3 및 실시예 1의 웰 흡광도임)(Where A is the absorbance of the control well not treated with the components and B is the absorbance of the wells of Comparative Examples 1 to 3 and Example 1 in which the respective components were treated)
실험은 4회 반복 수행하였으며, 그 결과를 하기 표 2에 나타내었다.The experiment was repeated four times, and the results are shown in Table 2 below.
상기 표 2의 결과에서, 적포도잎 추출물을 함유하는 비교예 1의 DPPH 소거 능력이 뛰어나, 체내 산화-환원 반응과 관련된 많은 생리적 작용에 영향을 미칠 것으로 판단되었다. 또한, 적포도잎 추출물에 베리 혼합물과 셀레늄을 혼합처리한 실시예 1도 항산화 활성이 유의적으로 증가하였다.The results of Table 2 above indicate that DPPH elimination ability of Comparative Example 1 containing red grape leaf extract was excellent and it was thought to affect many physiological actions related to the oxidation-reduction reaction in the body. In addition, the antioxidant activity of Example 1 in which the berry mixture and selenium were mixed with the grape leaf extract was also significantly increased.
[시험예 2] 시험관 내에서 활성산소 소거 효능[Test Example 2] Effect of active oxygen scavenging in vitro
세포내에서 항산화 물질의 작용에 대한 영향성을 확인하기 위하여, 시험관 내에서 UV에 의해 발생되는 활성 산소 소거능을 평가하는 실험을 통해 평가하였다. In order to confirm the effect of antioxidants on the action of intracellular antioxidants, experiments were carried out to evaluate the scavenging ability of active oxygen generated by UV in vitro.
세포 배양과 물질 처리는 다음과 같다. 본 실험에 사용한 Hacat 세포주(human keratinocyte cell line)는 Dr. N.E. Fusenig(Heidelberg, Germany)에게 기증받아 사용하였으며, 10% FBS, 100 IU/ml 페니실린과 100?g/ml 스트렙토마이신을 포함하는 DMEM(Dulbeccos Modification of Eagles Medium, 시그마사)을 배양액으로 하여 37℃ 배양기에서 공기(95%)와 CO2(5%)의 혼합기체를 지속적으로 공급하여 주며 배양하였다. Hacat 세포를 배양용기에 이식하고 24시간 후 배양액을 FBS를 처리하지 않은 DMEM으로 교체하고 활성을 측정하고자 하는 시료를 배양 세포에 처리하였다. 시험 시료를 넣고 24시간 배양 후에 HCSS(HEPES-buffered control salt solution)로 세척하여 남아 있는 배지를 제거하고 HCSS에 20 μM로 준비된 DCFH-DA(2',7'-dichlorodihydro-fluorescein diacetate, Molecular Probes, Inc)를 100 ml 가한 다음 37℃, 5% CO2 조건에서 20분간 배양하고 HCSS로 세척하였다. HCSS를 100 ml 가한 후 초기에 ROS로 산화된 DCF(dichlorofluorescein)의 형광 강도를 형광플레이트 리더(Ex=485 nm, Em=530 nm)로 측정하였다. 이후 UVB 30 mJ/㎠를 각각의 실험조건의 세기로 처리하고 처리직후 및 처리 3시간까지의 형광도를 형광플레이트 리더(Ex=485 nm, Em=530 nm)로 형광 강도를 측정하였다. 각 실험군은 표 1에 있는 비교예 1∼3 및 실시예 1을 1, 10 및 100 ppm씩 사용하였고, 그 결과는 하기 표 3에 나타내었다.Cell culture and material treatment are as follows. The Hacat cell line (human keratinocyte cell line) (Dulbecco's Modification of Eagles Medium, Sigma) containing 10% FBS, 100 IU / ml penicillin and 100 μg / ml streptomycin was used as a culture medium and incubated at 37 ° C In the incubator, a mixed gas of air (95%) and CO 2 (5%) was continuously supplied and cultured. Hacat cells were transplanted into a culture vessel, and after 24 hours, the culture medium was replaced with non-FBS-treated DMEM, and a sample to be assayed was treated with cultured cells. After incubation for 24 hours, the cells were washed with HEPES-buffered control salt solution to remove the remaining medium. DCFH-DA (2 ', 7'-dichlorodihydro-fluorescein diacetate, Molecular Probes, Inc) was added to each well and incubated at 37 ° C and 5% CO 2 for 20 minutes and washed with HCSS. The fluorescence intensity of DCF (dichlorofluorescein) initially oxidized to ROS after adding 100 ml of HCSS was measured with a fluorescent plate reader (Ex = 485 nm, Em = 530 nm). The fluorescence intensity was measured with a fluorescent plate reader (Ex = 485 nm, Em = 530 nm) immediately after the treatment and after 3 hours of treatment with UVB 30 mJ / Each experimental group used 1, 10 and 100 ppm of Comparative Examples 1 to 3 and Example 1 in Table 1, and the results are shown in Table 3 below.
※ 상기 과정에서 사용한 HCSS(HEPES-buffered control salt solution)의 조성은 다음과 같다: NaCl 120 mM(7.0128g/L), KCl 5 mM(0.37275g/L), MgCl2 1.6 mM(327ul/L), CaCl2 2.3 mM(0.2553g/L), 글루코스 15 mM(2.703g/L), HEPES 20 mM(4.766g/L) 및 NaOH 10 mM(0.4g/L).The composition of the HCSS (HEPES-buffered control salt solution) used in the above procedure was as follows: NaCl 120 mM (7.0128 g / L), KCl 5 mM (0.37275 g / L), MgCl 2 1.6 mM (327 ul / , CaCl 2 2.3 mM (0.2553 g / L), glucose 15 mM (2.703 g / L),
상기 표 3의 결과에서, 실시예 1에서 뛰어난 활성산소 소거 활성을 나타내었으며, 비교예 1 내지 3은 상대적으로 활성이 떨어지는 것으로 나타났다. 이는 세포내에서 발생한 활성 산소의 소거에 대해서는 그 작용성이 떨어짐을 의미하며 이는 활성산소 소거활성을 위해 필요한 세포내 물질 흡수 혹은 신호 전달능력이 상대적으로 낮음을 의미한다. 반면 실시예 1의 경우, 적포도잎 추출물의 실제 함량에 비해 훨씬 우수한 활성산소 소거 능력을 나타내었는데 이는 베리 혼합 추출물과 셀레늄을 더 혼합함으로써 시너지 효과를 얻을 수 있음을 의미하며, 이러한 시너지 효과는 물질의 세포내 흡수, 시그널링 혹은 산화촉진제의 역할 완화 및 안정화 등의 다양한 메커니즘에 의해 생겨날 수 있을 것으로 생각된다. The results of the above Table 3 show that the active oxygen scavenging activity was excellent in Example 1, and Comparative Examples 1 to 3 were relatively inferior in activity. This means that the action of the active oxygen in the cell is less effective for elimination of the active oxygen, which means that the intracellular substance absorption or signal transduction capacity required for the active oxygen scavenging activity is relatively low. On the other hand, in Example 1, the active oxygen scavenging ability was much better than the actual content of red grape leaf extract. This means that synergy can be obtained by further mixing the berry mixed extract and selenium, Such as intracellular uptake, signaling or role relaxation and stabilization of the oxidizing promoter.
[시험예 3] 시험관 내에서 자유라디칼 소거 효능[Test Example 3] Free radical scavenging effect in vitro
본 발명의 조성물이 생체 내에서 나타내는 자유라디칼 소거 효능을 실험하기 위하여 무모생쥐를 동물모델로 선정하여 실험하였다. 6-7주령의 암컷 무모생쥐 (hairless mouse, SKH, HR-1)를 하기 표 4에 기재한 바와 같이 대조군(정상군), UV 대조군, 비교예 4 및 실시예 2로 그룹 당 8마리씩으로 나누어 실험기간 동안 사육하였다.In order to examine the effect of the composition of the present invention on the free radical scavenging activity in vivo, hairless mice were selected as animal models. 6-7 week old female hairless mice (SKH, HR-1) were divided into a control group (normal group), a UV control group, and a control group (Comparative Example 4) They were raised during the experimental period.
대조군 및 UV 대조군은 0.5ml의 생리식염수를 경구 투여하였고, 비교예 4와 실시예 2는 고형분 기준으로 체중 kg당 167 mg의 파우더를 0.5 ml 식염수에 섞어 액체투여용 주사기를 이용하여 경구 투여하였다. 투여기간은 총 5주로 주 5일 동안 동일한 시간에 투여하였다. In the control and UV control groups, 0.5 ml of physiological saline was orally administered. In Comparative Example 4 and Example 2, 167 mg of powder per kg of body weight was mixed with 0.5 ml of saline per kg of body weight. The administration period was 5 weeks in total and 5 days in a week.
자유라디칼 소거활성 실험을 위해, 시험기간 종료 후 각 실험군의 실험 동물로부터 안구의 혈관에서 혈액 샘플을 1 ml씩 취하였으며, 이를 원심분리기를 이용하여(3000 rpm, 10분) 혈구와 혈장으로 분리하였고 상등액을 취하여 1.7 ml 마이크로 E-튜브에 담아 분석 직전까지 냉동시켜 보관하였다. For the free radical scavenging activity, 1 ml of blood samples were taken from the eyeballs of the experimental animals in each experimental group after the test period, and they were separated into blood cells and plasma using a centrifuge (3000 rpm, 10 minutes) The supernatant was taken and stored in 1.7 ml Micro-E tubes, frozen until just before analysis.
평가방법은 다음과 같다. ABTS(2,2'-Azino-bis(3-ethylbenzthiazoline 6-sulfonic acid))를 pH 5.0인 0.05 M의 인산-시트르산(phosphate-citrate) 버퍼에 최종 농도가 150 M이 되도록 첨가하여 ABTS 용액을 제조하였다. 상기 ABTS 용액에 과산화수소(H2O2)와 퍼옥시다아제를 각기 75 M과 2.5 M이 되도록 첨가하여 반응시켜 ABTS 라디칼(ABTS˙+)을 생성하였다. 혈장 샘플 20 ℓ를 180 ℓ의 ABTS 라디칼 용액에 첨가하고 완전히 혼합한 후, 상온에서 차광시킨 다음 60분간 반응시키고, 반응이 완료된 후 600 nm에서 시료의 흡광도를 측정하였다. 이와 동시에 pH 5.0인 0.05 M의 인산-시트르산 버퍼에 트롤록스를 최종농도가 10 mM, 2 mM, 1 mM, 100 M 및 10 M가 되도록 첨가하여 트롤록스 시료를 제조한 다음 상기 ABTS 라티칼 용액을 사용하여 위와 동일한 방법으로 반응시키고 흡광도를 측정하여 표준 곡선을 작성하였고, 그 결과를 도 1에 나타내었다. 혈장샘플의 자유기 소거능은 작성된 표준 곡선으로부터 도출된 하기 수학식 2를 이용하여 TEAC(Trolox Equivalence Antioxidant Activity) 값으로 나타내었으며, 그 결과는 표 5에 나타내었다. 여기에서, TEAC는 평가 샘플의 자유기 소거능을 이와 동등한 활성을 발휘하는 트롤록스의 용량으로 표시해 주는 것으로 항산화 물질 간 활성의 상대비교가 가능하게 해주는 단위이다(Miller NJ. et al., Clinical Science, 84, 407-412, 1993).The evaluation method is as follows. ABTS (2,2'-Azino-bis (3-ethylbenzthiazoline 6-sulfonic acid)) was added to 0.05 M phosphate-citrate buffer at pH 5.0 to a final concentration of 150 M Respectively. Hydrogen peroxide (H 2 O 2 ) and peroxidase were added to the ABTS solution at 75 M and 2.5 M, respectively, and reacted to produce the ABTS radical (ABTS˙ + ). 20 L of plasma samples were added to 180 L of ABTS radical solution, mixed thoroughly, shaded at room temperature, reacted for 60 min, and absorbance of the sample was measured at 600 nm after completion of the reaction. At the same time, Trolox was added to 0.05 M phosphate-citric acid buffer, pH 5.0, to a final concentration of 10 mM, 2 mM, 1 mM, 100 M and 10 M to prepare a Trolox sample. And the absorbance was measured to prepare a standard curve. The results are shown in FIG. The free radical scavenging ability of the plasma sample was represented by the Trolox Equivalence Antioxidant Activity (TEAC) value using the following equation 2 derived from the prepared standard curve, and the results are shown in Table 5. Here, TEAC is a unit that allows relative comparisons of antioxidant activity, by indicating the free eliminability of the evaluation sample in terms of the equivalent activity of trolox (Miller NJ et al., Clinical Science, 84, 407-412, 1993).
상기 표 5의 결과에서, 본 발명에 의한 실시예 2의 자유라디칼 소거능은 대조군 및 UV 대조군과 대비하여 월등히 우수하였고, 적포도잎 추출물만을 포함하는 비교예 4 보다도 2배 가까이 우수한 자유라디칼 소거능을 보이는 것을 확인할 수 있었다.From the results shown in Table 5, the free radical scavenging ability of Example 2 according to the present invention was much superior to that of the control and UV control groups, and showed a free radical scavenging ability twice as excellent as that of Comparative Example 4 containing only red grape leaf extract .
[시험예 4] 피부주형을 이용한 광노화 억제[Test Example 4] Suppression of photoaging using skin template
본 발명의 조성물이 광노화 증상에 미치는 영향을 조사하고자 시험예 3에서 사용한 동물모델을 이용하여 실험하였다. 경구 투여 후 2주부터 5주까지 대조군, UV 대조군, 비교예 4 및 실시예 2에 주 3회 태양광과 유사하게 UV를 조사하였다. 이때 실험기간 중 총 UV 조사량이 600 mJ/㎠이 되도록 하였다. 주름개선 효과의 객관적 판정을 위하여 부검 전 무모생쥐(hairless mouse)의 등쪽에서 실리콘 폴리머를 이용하여 피부 주형(replica)을 채취하였고, 피부의 주름 정도를 비교하기 위하여 피부 주름측정기(Skin Visiometer)를 이용하여 피부 표면의 이미지를 파일화하였다. 이는 도 2에 나타내었다.In order to investigate the effect of the composition of the present invention on photoaging symptoms, an experiment was conducted using the animal model used in Test Example 3. From 2 weeks to 5 weeks after the oral administration, the control, UV control, Comparative Example 4 and Example 2 were irradiated with UV light similar to sunlight three times a week. At this time, total UV irradiation amount was 600 mJ / ㎠ during the experiment. To determine the effect of wrinkle improvement, a skin polymer replica was taken from the dorsal side of a hairless mouse before the autopsy. To compare the degree of wrinkles of the skin, a skin visiometer was used And the image of the skin surface was filed. This is shown in Fig.
도 2의 결과에서 알 수 있듯이, 실시예 2의 무모생쥐(hairless mouse)의 피부 표면의 주름의 굴곡이나 정도가 UV 대조군 및 비교예 4에 비해 현저하게 완화되어 본 발명에 의한 항산화용 조성물이 자외선에 의한 피부주름을 개선시킴으로써 광노화 현상을 억제하는데 효과가 있음을 확인할 수 있었다. As can be seen from the results of FIG. 2, the bending degree of the wrinkles on the skin surface of the hairless mouse of Example 2 was remarkably alleviated as compared with the UV control and Comparative Example 4, It was confirmed that it is effective in suppressing the photoaging phenomenon by improving the wrinkles of the skin by the skin.
[시험예 5] 간이임상실험[Test Example 5]
연령 25∼45세의 성인여자 40명을 2군으로 나누고, 실험군은 참조예 1의 적포도잎 추출물 1 g, 참조예 2의 베리 혼합물 0.2 g, 셀레늄 0.2 g, 유당 1 g, 글리세린 1.1 g 및 자일리톨 0.5 g을 혼합하여 통상의 방법에 따라 1환당 4 g으로 하여 제조한 환을 1일 1정씩 30일간 복용시켰고, 대조군은 상기 실험군에 적용한 환에서 유효성분들(적포도잎 추출물, 베리 혼합물 및 셀레늄) 대신 포도당 1.4 g을 첨가하여 제조한 환을 동일한 방법으로 복용시켰다. 시험 종료 후 피부 상태에 대한 설문조사를 각각 실시하였으며, 그 결과는 하기 표 6에 나타내었다. Forty adult women aged 25 to 45 years were divided into two groups. One group of the grape leaf extract of Reference Example 1, 0.2 g of the berry mixture of Reference Example 2, 0.2 g of selenium, 1 g of lactose, 1.1 g of glycerin, And 0.5 g of xylitol were mixed in a usual manner to prepare 4 g per one ring. The control group was administered with the active ingredients (red grape leaf extract, berry mixture and selenium ) Was replaced with 1.4 g of glucose, and the ring was prepared by the same method. After the test, a questionnaire about the skin condition was conducted, and the results are shown in Table 6 below.
설문항목
Survey item
(4명)20's
(4 people)
(10명)30s
(10 people)
(6명)40s
(6 people)
(20명)Sum
(20 people)
(6명)20's
(6 people)
(8명)30s
(8 people)
(6명)40s
(6 people)
(20명)Sum
(20 people)
상기 표 6의 결과에서 알 수 있는 바와 같이, 실험군은 대조군에 비해 피부의 촉촉한 감이나 탄력감을 느끼는 비율이 높았고, 잔주름이 줄었다고 느꼈으며 화장이 잘 받는다고 응답하는 사람이 많았다. 이를 통해 적포도잎 추출물 함유 혼합 항산화제를 함유하는 조성물을 사용할 경우 피부 상태가 전반적으로 개선될 수 있음을 알 수 있었다.As can be seen from the results in Table 6, the experimental group showed a higher rate of feeling a moisturizing or elastic feeling of the skin than the control group, and many people felt that the fine lines had decreased and the makeup was well received. It was found that the use of a composition containing a mixed antioxidant containing red grape leaf extract can improve the skin condition as a whole.
본 발명이 제공하는 경구용 피부미용 개선용 조성물은 하기와 같이 여러 가지 제형으로 응용 가능하지만, 이에 한정되는 것은 아니다.The composition for oral skin beauty improvement provided by the present invention can be applied to various formulations as described below, but the present invention is not limited thereto.
[제형예 1] 연질캅셀제[Formulation Example 1] Soft capsule
상기 실시예 4의 항산화제 200 mg, 대두추출물 50 mg, 대두유 180 mg, 홍삼추출물 50 mg, 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시틴 6 mg을 혼합하고 통상의 방법에 따라 1캡슐당 400 mg씩 충진하여 연질캅셀을 제조하였다.The mixture was mixed with 200 mg of the antioxidant of Example 4, 50 mg of soybean extract, 180 mg of soybean oil, 50 mg of red ginseng extract, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow pearls and 6 mg of lecithin, 400 mg per well was filled to prepare a soft capsule.
[제형예 2] 정제[Formulation Example 2] Tablets
상기 실시예 4의 항산화제 200 mg, 대두추출물 50 mg, 포도당 100 mg, 홍삼추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정하였다. 내용물의 최종 중량은 400 mg으로 하였다.After granules were formed by mixing 200 mg of the antioxidant of Example 4, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate, and 40 mg of 30% ethanol, Dried at 60 ° C and tableted using a tablet machine. The final weight of the contents was 400 mg.
[제형예 3] 과립제[Formulation Example 3]
상기 실시예 4의 항산화제 200 mg, 대두추출물 50 mg, 포도당 100 mg, 홍삼추출물 50 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.200 mg of the antioxidant of Example 4, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, And then filling the pores. The final weight of the contents was 1 g.
[제형예 4] 드링크제[Formulation Example 4] Drinking agent
상기 실시예 4의 항산화제 200 mg, 대두추출물 50 mg, 포도당 10 g, 홍삼추출물 50 mg, 구연산 2 g 및 정제수 188 g을 혼합하고 병에 충진하였다. 내용물의 최종 중량은 100 ml로 하였다.200 mg of the antioxidant of Example 4, 50 mg of soybean extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 188 g of purified water were mixed and filled in a bottle. The final weight of the contents was 100 ml.
도 1은 본 발명의 시험예 3에 기재된 트롤록스(trolox) 농도 변화에 따른 흡광도 저해율의 표준 곡선(standard curve)을 보여준다. Fig. 1 shows a standard curve of absorbance inhibition rate according to the change in trolox concentration described in Test Example 3 of the present invention.
도 2는 대조군, UV 대조군, 비교예 4 및 실시예 2에 대한 피부 주형의 사진이다.2 is a photograph of skin molds for the control, UV control, Comparative Examples 4 and 2.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090032841A KR101558184B1 (en) | 2009-04-15 | 2009-04-15 | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090032841A KR101558184B1 (en) | 2009-04-15 | 2009-04-15 | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100114349A KR20100114349A (en) | 2010-10-25 |
KR101558184B1 true KR101558184B1 (en) | 2015-10-08 |
Family
ID=43133563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090032841A KR101558184B1 (en) | 2009-04-15 | 2009-04-15 | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101558184B1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101059248B1 (en) * | 2011-05-06 | 2011-08-25 | 한현정 | Seven extracts and making method using the same |
KR101287021B1 (en) * | 2012-12-31 | 2013-07-17 | 주식회사 제닉 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin using supersonic method and manufacturing method thereof |
KR101901412B1 (en) | 2017-06-28 | 2018-09-21 | 아주대학교산학협력단 | Composition Comprising Vitis Vinifera Leaf Extract for Preventing or Treating Hearing Loss |
KR102572991B1 (en) * | 2021-04-16 | 2023-08-31 | 재단법인 포항테크노파크 | A uv protection of diethylamino hydroxybenzoyl hexylbenzoate, plant extracts including pinus rigida mill extracts, and a cosmetic composition comprising the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100342543B1 (en) | 1993-12-21 | 2002-12-11 | 인데나 에스.피.아 | Compositions containing lycopene combined with polyphenols to prevent damage due to abnormal production of free radicals |
JP2005535566A (en) | 2002-03-12 | 2005-11-24 | コグニス・イベリア・ソシエダッド・リミターダ | Antioxidant preparation |
-
2009
- 2009-04-15 KR KR1020090032841A patent/KR101558184B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100342543B1 (en) | 1993-12-21 | 2002-12-11 | 인데나 에스.피.아 | Compositions containing lycopene combined with polyphenols to prevent damage due to abnormal production of free radicals |
JP2005535566A (en) | 2002-03-12 | 2005-11-24 | コグニス・イベリア・ソシエダッド・リミターダ | Antioxidant preparation |
Also Published As
Publication number | Publication date |
---|---|
KR20100114349A (en) | 2010-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11039999B2 (en) | Compositions suitable for treating cutaneous signs of aging | |
WO2006075865A1 (en) | Skin-condition improving composition comprising vaccinium uliginosum extract and method for preparation thereof | |
KR101728686B1 (en) | Cosmetic composition containing snail mucus fed with berry and fruit priducing method thereof | |
KR101402550B1 (en) | Antioxidizing Functional Cosmetic Compositions for Containing Extracted/Fermented Dendropanax morbifera Products and Functional Cosmetics Produced Thereby | |
KR20160091166A (en) | natural cosmetic composition for removing callus and improving skin barrier function | |
KR101558184B1 (en) | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium | |
KR102161179B1 (en) | Antioxidative composition comprising extract of red tea stem | |
KR101558182B1 (en) | Skin External Composition Containing Extracts of Chrysanthemum indicum var. albescens | |
KR20090013293A (en) | Anti-wrinkle cosmetic composition with anti-aging effect containing pear extracts | |
KR101315325B1 (en) | A composition for skin external application containing antioxidant components for improving skin wrinkle and skin whitening | |
KR101252548B1 (en) | A cosmetic composition containing as available ingredient the extracts of Pinus koraiensis | |
KR101176526B1 (en) | Cosmetic Composition Comprising the extract of Spiraea prunifolia var.simpliciflora as Active Ingredient | |
JP2010111602A (en) | Antioxidant | |
KR101509603B1 (en) | Composition for skin external application containing for improving skin wrinkle or skin Whitening | |
KR102072990B1 (en) | Functional cosmetic compositions comprising complex extract of gold kiwi peel and banana peel as effective ingredient, and manufacturing method thereof | |
KR20090002369A (en) | Cosmetic composition with the antioxidant effect protecting skins aging | |
KR20190048935A (en) | Cosmetic composition comprising extract of red onion fermented by aureobasidium pullulans | |
KR100604244B1 (en) | Cosmetic composition containing Solanum Lycopersicum MILL.Extract | |
KR20130052288A (en) | Cosmetic composition comprising the hot spring water extract of nelumbo nucifera gaertner as active ingredient | |
KR101363029B1 (en) | The cosmetic composition for anti-oxident and anti-aging of the skin comprising the Gelidium amansii, Undaria pinnatifida, wheat bud and Monarda horsemint | |
KR20090123266A (en) | Cosmetic compositions containing the extracts of aster spathulifolius maxim or aster spathulifolius var.oharai, and method of preparing the extracts | |
KR102582377B1 (en) | Composition comprising zizania latifolia extract for inhibiting or preventing skin disease and skin damage caused by ultroviolet a | |
JP2018138525A (en) | Vitamin C transporter production promoter and vitamin C absorption promoting composition | |
KR100563673B1 (en) | Health Foods for the care of skin wrinkle | |
JP2006248909A (en) | Anti-inflammatory agent obtained by irradiation of laser beam and exhibiting free radical scavenging action, food formulation and cosmetic formulaton comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190926 Year of fee payment: 5 |